Drugs / CT1812
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05248672 | Feb → Jun 2022 | Alzheimer disease | Cognition Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05225389 | Dec 2021 → Jan 2022 | Alzheimer disease | Cognition Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03716427 | Nov → Dec 2016 | — | Cognition Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04735536 | Jul 2020 → Apr 2023 | Alzheimer disease | Cognition Therapeutics | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06961760 | — | Lewy body dementia | Cognition Therapeutics | No longer available | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT03522129 Comparator | May 2018 → Feb 2019 | Alzheimer disease | Cognition Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02570997 Comparator | Sep 2015 → May 2016 | cognitive disorder | Cognition Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT03493282 Comparator | Mar 2018 → Oct 2020 | Alzheimer disease | Cognition Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT02907567 Comparator | Sep 2016 → Aug 2017 | Alzheimer disease | Cognition Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05531656 Comparator | Jun 2023 → Apr 2027 expected | Alzheimer disease | Cognition Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05893537 Comparator | Jun 2023 → Mar 2025 | dry age related macular degeneration | Cognition Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05225415 Comparator | May 2022 → Nov 2024 | Lewy body dementia | Cognition Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03507790 Comparator | Oct 2018 → May 2024 | — | Cognition Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT1812 | “Zervimesine (CT1812) was shown to be safe and well tolerated in a study of healthy volunteers and in Phases 1 and 2 studies of participants with mild to moderate AD and DLB.” NCT06961760 ↗ |
| Known as | zervimesine | “Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB).” PMID 41416579 ↗ Dec 2025 |
| Action | Inhibit | “CT1812 is an orally bioavailable, brain penetrant small molecule antagonist of the sigma-2 receptor complex that appears safe and well tolerated in healthy elderly volunteers.” PMID 33559354 ↗ Feb 2021 |
| Modality | Small molecule | “CT1812 is an orally bioavailable, brain penetrant small molecule antagonist of the sigma-2 receptor complex that appears safe and well tolerated in healthy elderly volunteers.” PMID 33559354 ↗ Feb 2021 |
| Route | Oral | “evaluate the safety and tolerability of oral CT1812, administered for 28 days” NCT02907567 ↗ |
| Target | TMEM97 | “small molecule modulator of the sigma-2 receptor (S2R/TMEM97)” PMID 41943055 ↗ Apr 2026 |